Kyverna Therapeutics, Inc. Line of Credit Facility, Maximum Borrowing Capacity
Kyverna Therapeutics, Inc. (KYTX) had Line of Credit Facility, Maximum Borrowing Capacity of $150.00 million as of 2025-10-31, per its 10-Q filed 2026-05-12.
Financial Statements › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2026-05-12
- 2025-10-31: Line of Credit Facility, Maximum Borrowing Capacity $150.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2025-10-31 | $150.00M 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |